bluebird bio Beats Its Q4 Revenue Target but Misses on EPS

bluebird bio (NASDAQ: BLUE) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The clinical-stage biotech's stock price fell a bit in after-hours trading as investors reacted to the mixed report.